The Liver Fibrosis Market was valued at USD 25.24 billion in 2025 and is projected to reach USD 59.43 billion by 2033, growing at a CAGR of 11.30% from 2026 to 2033. The market is witnessing steady expansion driven by the rising global burden of chronic liver diseases, increasing prevalence of hepatitis B and C infections, non-alcoholic fatty liver disease (NAFLD), and growing alcohol-related liver disorders. Advancements in non-invasive diagnostic technologies and improved awareness regarding early-stage liver disease detection are further supporting market growth.
The increasing demand for early and accurate fibrosis assessment, coupled with a shift from invasive liver biopsies toward imaging-based and serum biomarker diagnostic methods, is accelerating adoption across healthcare systems. In addition, expanding pharmaceutical R&D for anti-fibrotic therapies and growing screening initiatives in high-risk populations are strengthening market penetration. The integration of AI-enabled imaging and elastography solutions in clinical practice is further enhancing diagnostic precision and driving the transition toward more efficient liver disease management.